Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) was upgraded by analysts at Wells Fargo & Company from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday, Zacks.com reports.
Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday. Wolfe Research reiterated an “outperform” rating and set a $51.00 price target on shares of Celldex Therapeutics in a report on Wednesday. Stifel Nicolaus began coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $63.83.
Read Our Latest Stock Analysis on CLDX
Celldex Therapeutics Stock Down 8.8 %
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. As a group, equities research analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current year.
Hedge Funds Weigh In On Celldex Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Celldex Therapeutics during the 2nd quarter valued at approximately $76,000. Teachers Retirement System of The State of Kentucky raised its holdings in Celldex Therapeutics by 32.0% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 40,558 shares of the biopharmaceutical company’s stock valued at $1,501,000 after acquiring an additional 9,829 shares during the period. Novo Holdings A S purchased a new stake in shares of Celldex Therapeutics during the second quarter worth $31,458,000. Algert Global LLC boosted its holdings in shares of Celldex Therapeutics by 75.6% in the second quarter. Algert Global LLC now owns 75,614 shares of the biopharmaceutical company’s stock worth $2,798,000 after acquiring an additional 32,564 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Celldex Therapeutics by 47.5% in the second quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after purchasing an additional 272,389 shares in the last quarter.
About Celldex Therapeutics
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
See Also
- Five stocks we like better than Celldex Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- REITs on the Rise After Rate Cuts: Where to Invest Now
- Where to Find Earnings Call Transcripts
- Is Viking Therapeutics Ready For Another Surge?
- Comparing and Trading High PE Ratio Stocks
- AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.